Bolt Biotherapeutics (BOLT) to Release Earnings on Thursday

Bolt Biotherapeutics (NASDAQ:BOLT) is expected to be issuing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Bolt Biotherapeutics to post earnings of ($3.3867) per share and revenue of $0.50 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 19, 2026 at 4:00 PM ET.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%. The business had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $1.50 million.

Bolt Biotherapeutics Stock Performance

Bolt Biotherapeutics stock opened at $3.99 on Tuesday. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.51 and a quick ratio of 3.51. Bolt Biotherapeutics has a 1-year low of $3.75 and a 1-year high of $7.20. The firm has a market capitalization of $7.67 million, a P/E ratio of -0.24 and a beta of 1.18. The company’s 50-day moving average is $4.17 and its 200 day moving average is $4.65.

Wall Street Analyst Weigh In

BOLT has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Friday, July 17th. Rodman & Renshaw started coverage on Bolt Biotherapeutics in a research note on Thursday, May 28th. They issued a “buy” rating and a $22.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Bolt Biotherapeutics has an average rating of “Hold” and a consensus target price of $34.67.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BOLT. Squarepoint Ops LLC increased its stake in Bolt Biotherapeutics by 19.8% during the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after purchasing an additional 2,448 shares in the last quarter. Shay Capital LLC purchased a new stake in shares of Bolt Biotherapeutics during the third quarter valued at $85,000. Susquehanna International Group LLP purchased a new stake in shares of Bolt Biotherapeutics during the third quarter valued at $89,000. Finally, Renaissance Technologies LLC increased its position in shares of Bolt Biotherapeutics by 92.2% in the 4th quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock valued at $301,000 after acquiring an additional 26,400 shares during the period. 86.70% of the stock is currently owned by hedge funds and other institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.